Equities analysts expect ContraFect Co. (NASDAQ:CFRX – Get Rating) to post earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks. Zero analysts have provided estimates for ContraFect’s earnings, with estimates ranging from ($0.31) to ($0.27). ContraFect reported earnings per share of ($0.27) in the same quarter last year, which suggests a negative year over year growth rate of 7.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that ContraFect will report full year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($1.69) to ($1.09). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.33) to ($1.05). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for ContraFect.
ContraFect (NASDAQ:CFRX – Get Rating) last announced its quarterly earnings data on Monday, May 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.20).
Large investors have recently bought and sold shares of the business. Wedmont Private Capital purchased a new position in ContraFect during the 4th quarter valued at about $25,000. Moody Lynn & Lieberson LLC acquired a new stake in shares of ContraFect during the 4th quarter worth about $26,000. Mayflower Financial Advisors LLC acquired a new stake in shares of ContraFect during the 4th quarter worth about $26,000. Envestnet Asset Management Inc. acquired a new stake in shares of ContraFect during the 1st quarter worth about $41,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of ContraFect during the 4th quarter worth about $46,000. Hedge funds and other institutional investors own 59.39% of the company’s stock.
Shares of CFRX opened at $3.35 on Tuesday. The company has a 50-day simple moving average of $3.63 and a 200-day simple moving average of $3.21. The company has a market capitalization of $131.76 million, a PE ratio of -3.76 and a beta of 0.51. ContraFect has a 52-week low of $2.11 and a 52-week high of $4.76.
ContraFect Company Profile (Get Rating)
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.
- Get a free copy of the StockNews.com research report on ContraFect (CFRX)
- DoubleVerify Holding Stock attempts a Double Bottom
- Teladoc Health Stock is Pricing Right
- The Key Number That Explains Why CrowdStrike May Power Higher
- Two Consumer Staples With Bright Outlook For Dark Times
- Datadog: A Unicorn Cloud Stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.